Stay updated on Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Sign up to get notified when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.11 to v2.16.12.
    Difference
    0.3%
    Check dated 2025-08-17T01:32:22.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.3%
    Check dated 2025-08-09T19:59:02.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    The page now includes a disclaimer about the U.S. government's lack of review for the safety and science of studies listed, and it notes the termination of the drug Flotetuzumab for certain conditions. Additionally, the HHS Vulnerability Disclosure section has been added.
    Difference
    100%
    Check dated 2025-08-02T14:41:14.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    The webpage has removed important disclaimers regarding the U.S. government's review of clinical studies and the termination of a specific drug study, while adding a note about server errors and a reminder about the official nature of the website.
    Difference
    100%
    Check dated 2025-07-26T12:24:58.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.5 to version 2.16.6.
    Difference
    0.3%
    Check dated 2025-07-19T11:07:42.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    A service alert has been added indicating planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.
    Difference
    4%
    Check dated 2025-07-12T07:29:42.000Z thumbnail image

Stay in the know with updates to Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.